BioSpace News Archive

Cabaletta Bio, Inc. announced that Steven Nichtberger, M.D., President and Chief Executive Officer, will present a pre-recorded company presentation at the H.C. Wainwright BioConnect Conference, which will become available for on-demand viewing on Monday, January 10, 2022 at 7:00 a.m. ET.

Exclusive license from AstraZeneca adds a unique candidate and a broad library of compounds to Ovid’s franchise of potential first-in-class anti-epileptic therapies.

Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company’s executive management team will participate in the following investor conferences in the first quarter of 2022.

Apellis Pharmaceuticals today announced that the company will present virtually at the 40th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2022 at 8:15 a.m. ET.

Altimmune, Inc. today announced that Dr. Scott Harris, Chief Medical Officer at Altimmune, will give an oral and a poster presentation on pemvidutide, the Company’s novel, investigational GLP-1/Glucagon dual receptor agonist under development for the treatment of obesity and non-alcoholic steatohepatitis (NASH), the most severe form of non-alcoholic fatty liver disease (NAFLD).

Alpha Tau Medical Ltd. announced today that it has been notified by HekaBio K.K., its clinical trial partner in Japan , that recruitment has been completed in its open-label multi-center pivotal study evaluating the Alpha DaRT.

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will participate at the H.C. Wainwright BIOCONNECT Virtual Conference taking place January 10-13, 2022.

Xeris Biopharma Holdings, Inc. today announced that on January 2, 2022, it entered into a securities purchase agreement in connection with a private placement (the “Private Placement”) with an affiliate of Armistice Capital, LLC.

CinCor Pharma, Inc. today announced that it has launched an initial public offering of 11,000,000 shares of its common stock pursuant to a registration statement on Form S-1 filed with the Securities and Exchange Commission.

Viking Therapeutics, Inc. today announced that its chief executive officer, Brian Lian , Ph.D., will deliver a corporate presentation as part of the H.C. Wainwright BioConnect 2022 Conference.